Track Nexentis Technologies Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Nexentis Technologies Inc. NXTS · Stock Open Nexentis Technologies Inc. in new tab

1.94 USD
Add to portfolio
EPS
-17.14
P/B
0.11
ROE
-119.61
Beta
1.86
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateAug. 13, 2026
EPS-17.14
Book Value17.76
Price to Book0.11
Debt/Equity3.68
% Insiders21.174%

DCF Valuation

Tweak assumptions to recompute fair value for Nexentis Technologies Inc. (NXTS)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Nexentis Technologies Inc. Logo Nexentis Technologies Inc. Analysis (NXTS)

Israel Basic Materials Official Website Stock

Is Nexentis Technologies Inc. a good investment? Nexentis Technologies Inc. (NXTS) is currently trading at 1.94 USD.

Earnings Schedule: Nexentis Technologies Inc. is expected to release its next earnings report on Aug. 13, 2026.

Investor FAQ

Does Nexentis Technologies Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Nexentis Technologies Inc.?

Nexentis Technologies Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Aug. 13, 2026. The company currently has a trailing EPS of -17.14.

Company Profile

Nexentis Technologies Inc., through its subsidiary, develops therapeutics related to cancer and inflammatory metabolic diseases. It operates through two segments, Biotechnology Activity and Renewable Energy Projects. The company's pipeline includes MITOLINE, an algorithm used to perform multiple sequence/ structure pairwise alignments which could then be used for generating a 3D comparative model of potentially all mitochondrial carrier proteins; cloud-based computational chemistry platform; and novel in-vitro screening platforms; and advanced 3D NSCLC tumor spheroid systems.The company was formerly known as N2OFF, Inc. and changed its name to Nexentis Technologies Inc. in February 2026. Nexentis Technologies Inc. was incorporated in 2009 and is headquartered in Ness Ziona, Israel.

Exchange Ticker
NASDAQ NXTS
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion